Small-molecule inhibitors of tankyrase have been investigated for targeted cancer therapy, as they potently inhibit the pathological Wnt signaling activity in colorectal cancer cells by stabilizing axin and axin2 (Huang et al., 2009). Here, AXIN1 is linked to colorectal cancer.